Embodiments of the disclosure are directed to biomarkers, or a panel of biomarkers, that determine progression of Alzheimer's disease, and methods of use thereof.

Assay methods for detecting the presence or amount of VCAM-1 or calprotectin in a sample using fluorescence resonance energy transfer (FRET).

The present invention relates to endothelial cell biomarkers and diagnostic and prognostic methods for vascular diseases, including cardiovascular and cerebrovascular diseases. The invention also provides compositions for detecting endothelial cell biomarkers (e.g., endothelial cell-derived exosome biomarkers) as well as compositions and methods useful for treating vascular diseases (e.g., atherosclerotic cerebrovascular disease).

An assay method for detecting the presence or amounts of VCAM-1 and A2M in a sample using fluorescence resonance energy transfer (FRET).

The present invention concerns the use of VCAM-1, ICAM-1 and/or PlGF as biomarkers for predicting the outcome of the treatment with aflibercept, or ziv-aflibercept of a patient suspected to suffer from a cancer.

The present invention provides biomarker-based methods for diagnosing stroke in a patient suspected of having suffered a stroke, and also for discriminating between ischemic stroke and transient ischemic attack. Substrates comprising probes for specific combinations of biomarkers useful in the methods of the invention are also described.

An assay method for detecting the presence or amounts of VCAM-1 and A2M in a sample using fluorescence resonance energy transfer (FRET).

An assay method for detecting the presence or amounts of VCAM-1 and A2M in a sample using fluorescence resonance energy transfer (FRET).

The present invention relates to endothelial cell biomarkers and diagnostic and prognostic methods for vascular diseases, including cardiovascular and cerebrovascular diseases. The invention also provides compositions for detecting endothelial cell biomarkers (e.g., endothelial cell-derived exosome biomarkers) as well as compositions and methods useful for treating vascular diseases (e.g., atherosclerotic cerebrovascular disease).

The invention provides an antibody or fragment thereof that specifically binds to human endothelial vascular cell adhesion molecule-1 (VCAM-1), wherein the antibody or fragment thereof binds to the extracellular domain of VCAM-1, and wherein the antibody or fragment thereof binds to VCAM-1 when expressed on endothelial cells, wherein the antibody or fragment thereof is a human or humanized antibody, or fragment thereof.